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well-known biological obstacle: the blood-
brain barrier (BBB). The BBB consists of 
brain capillary endothelial cells, pericytes, 
astrocytes, and neurons all referred to as 
the neurovascular unit (NVU).[3] It repre-
sents a multicellular interface separating 
bloodstream and brain parenchyma, 
maintaining a constant homeostatic brain 
environment. After intravenous injection, 
only some lipophilic molecules penetrate 
to the brain parenchyma in therapeuti-
cally relevant concentrations, and 98% of 
neuroactive drugs cannot pass the BBB.[4] 
Currently, therapeutics can be delivered 
to the central nervous system (CNS) via 
several ways. Either the drug can circum-
vent the BBB after systemic administra-
tion or it has to be applied by invasive 
methods involving a high risk of severe 
side effects.[5] Possible approaches are, for example, opening of 
the tight junctions by osmotic disruption[6] or ultrasound[7] and 
direct intracerebral infusion or implantation.[8] In rare cases, 
such as traumatic brain injury or cancer, the pathological 
mechanisms by themselves, affecting BBB integrity, might 
offer the possibility to access the CNS.[9]
Since virtually every neuron has its own connection to a 
microvessel,[10] the approach to deliver drugs via the NVU inter-
face is one of the most promising strategies to efficiently target 
the brain.[11] In the past few years various nanoparticle (NP) types 
have been investigated to develop nanosystems meeting the 
needs of effective therapies for neurological diseases,[12] also 
leading to a broader understanding of the mechanism of NP 
uptake in the brain.[13] Among the many achievements, den-
drimers showed high potential for a noninvasive therapy. 
Several examples of inherent dendrimeric therapeutic poten-
tial have been presented: (a) antiprion,[15,16] b) antitoxin,[17] and 
c) antiamyloidogenic[18] effects. Additionally, dendrimers repre-
sent a perfect platform for CNS drug conjugation. For several 
neuropathologies multiple suitable dendrimer–drug conju-
gates have been introduced to the scientific community, like 
for the treatment of (a) Parkinson’s disease (dendrigraft poly-
l-lysine-PEG-Angiopep),[19] (b) hypoxia- and stroke-mediated 
hypoxia (HIF-1α siRNA/2G-NN16 carbosilane dendrimer),[20] 
(c) glioblastoma (G3-succinamic acid dendrimer-curcumin),[21] 
and (d) HIV-1 infection (2G-(SNMe3I)11-FITC cationic car-
bosilane).[22] For instance, Kannan and co-workers have 
published an impressive history in dendrimer applications 
improving the treatment of neuroinflammation. Observed 
Neurological disorders are undoubtedly among the most alarming diseases 
humans might face. In treatment of neurological disorders, the blood-brain 
barrier (BBB) is a challenging obstacle preventing drug penetration into the 
brain. Advances in dendrimer chemistry for central nervous system (CNS) 
treatments are presented here. A  poly(amido)amine (PAMAM) dendrimer 
bioconjugate with a streptavidin adapter for the attachment of dendrons or 
any biotinylated drug is constructed. In vitro studies on porcine or murine 
models and in vivo mouse studies are performed and reveal the permeation 
of dendronized streptavidin (DSA) into the CNS. The bioconjugate is taken 
up mainly by the caveolae pathway and transported across the BBB via 
transcytosis escaping from lysosomes. After transcytosis DSA are delivered 
to astrocytes and neurons. Furthermore, DSA offer high biocompatibility in 
vitro and in vivo. In summary, a new strategy for implementing therapeutic 
PAMAM function as well as drug delivery in neuropathology is presented here.
Drug Delivery
1. Introduction
Neurological diseases are a growing challenge in health care 
since, with prolonged aging, the number of patients will 
increase, with consequent high social impact due to severe 
morbidity and mortality.[1] Although the scientific achievements 
are constantly providing possible therapeutic molecules,[2] 
adequate treatments are still an unmet medical need, because 
systemically administered drugs are often ineffective due to a 
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uptake of poly(amido)amine (PAMAM) dendrimers in acti-
vated microglia and astrocytes in a model of cerebral palsy 
(CP) lead to the development of a successful dendrimer-based 
N-acetyl-l-cysteine (D-NAC) therapy of CP.[23] With neutral 
dendrimers a rapid 100-fold greater brain uptake compared to 
free drug could be achieved.[24] In a recent study the genera-
tion effect of hydroxyl PAMAM dendrimers in a canine model 
of induced brain injury could reveal much better pharmacoki-
netics and biodistribution of G6 dendrimers compared to G4 
dendrimers.[25] Furthermore, a successful antineuroinflam-
matory effect could be obtained for the treatment of the Rett 
syndrome, a pervasive developmental disorder. Although in 
this case D-NAC significantly improved behavioral outcomes, 
it could not prevent the lethal outcome.[26] The need of very 
careful investigations presenting new CNS therapeutic strate-
gies was revealed by the case of poly(propyleneimine) glyco-
dendrimers, which offer antiamyloidogenic effects but at the 
same time cause cognitive decline in WT mice.[18] Despite the 
investigated and described dendrimer systems for CNS appli-
cations, dendrimers with high biocompatibility, new linker 
strategies, and possibilities to transport biologicals (e.g., ther-
apeutic proteins) are eagerly awaited as highlighted in the 
review articles by Leiro et al. and Mignani et al.[14,27]
Dendrimers are highly branched globular macromolecules 
built of branched monomers on a small core molecule. The 
advantages of using dendrimers are control over size, liquid 
solubility, and a multitude of functionalization possibilities.[28] 
However, dendrimer synthesis is laborious and the balance 
between toxicity and biodegradability is highly dependent on 
the scaffold. Indeed, non-biodegradable dendrimers are highly 
associated with in vivo toxicity. Therefore, the use of biodegrad-
able dendrimers is strongly encouraged for biomedical appli-
cations.[29] Since the core of a dendrimer is generally inconse-
quential toward targeting and recognition, substituting it with 
a protein core provides an elegant approach toward both syn-
thesis and biocompatibility without compromising the mono-
Adv. Sci. 2018, 5, 1700897
Figure 1. DSA synthesis and investigated mechanism of biological application. A) Scheme of dendronized streptavidin assembly with detailed G3 
dendron structure. B) Schematic illustration of in vivo study design for G3-DSA transport from bloodstream to the brain.
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dispersed nature of both species. Specifically, the dendronized 
streptavidin (DSA) mimics endogenous proteins with a size of 
5 nm and a patched surface using a streptavidin adapter coated 
by PAMAM dendrimers (DSA) (Figure 1A). To our knowledge, 
the presented simple and elegant dendrimer system would 
allow for the first time to employ both inherent therapeutic 
functions of PAMAM dendrimers[16,17,30,31] and therapeutic 
effects of multiple drugs (including biologicals) in the same 
system attached to the streptavidin core by biotin-click-chem-
istry obtaining a new flexible synergistic nanoplatform.
Two generations of PAMAM dendrimers with a different 
number of positive charges were designed and their ability to 
cross the BBB and reach target cells in the CNS combined to a 
streptavidin adapter was assessed.
In our study, we have investigated the most relevant features 
of the bioconjugate and we could successfully address the fol-
lowing questions: (I) Are DSA taken up by endothelial cells and 
transported in an in vitro BBB model from luminal to abluminal? 
(II) Which are the underlying mechanisms of the transport? (III) 
Does the generation of PAMAM dendrimers influence uptake 
and transport efficiency? (IV) Do DSA affect vitality of NVU 
cells? (V) Are DSA able to cross the BBB and how are they bio-
distributed in vivo? (VI) Do they affect the BBB integrity in vivo?
We could successfully demonstrate that DSA were taken 
up by the endosomal pathway, transcytosed in vitro and in 
vivo across the BBB and taken up in target cells with higher 
efficiency for the third generation of DSA (Figure 1B). A high 
biocompatibility could be observed in impedance analysis (elec-
tric cell–substrate impedance sensing (ECIS), epithelial volt/
ohm meter (EVOM), CellZscope), in viability assays in vitro, as 
well as in Evans blue (EB) permeability assays in vivo.
With this new generation nanosystem, we aim to overcome 
the BBB with a noninvasive and biocompatible compound, 
which employs transcytosis as an endogenous transport system 
in order to apply PAMAM dendrimer antitoxin, antiprion or 
antiviral function in CNS or even deliver biopharmaceuticals 
(macromolecules) to the brain with high efficiency.
2. Results and Discussion
2.1. DSA Are Taken Up by Brain Endothelial Cells In Vitro
The tightly connected layer of brain endothelial cells repre-
sents the first obstacle to the entry of molecules into the CNS. 
Therefore, we investigated the ability of differently charged 
DSA (G2-DSA and G3-DSA) to be taken up by bEnd.3 cells 
in vitro. After 24 h incubation with DSA (rhodamine cova-
lently labeled streptavidin), 3D reconstructions of confocal 
z-stacks revealed the presence of NP-containing-vesicles 
in the cell cytosol of treated samples compared to control 
(CTR) untreated cells (Figure 2A). Quantitative analysis 
showed significant uptake for both generations of DSA with 
a significantly higher number of NP-containing-vesicles 
Adv. Sci. 2018, 5, 1700897
Figure 2. DSA uptake in bEnd.3 cells. A) Confocal 3D-image of DSA (red) uptake. B) Quantification of DSA-positive vesicles per cell. n = 28 ROIs from 
three cultures, one-way ANOVA, ***p < 0.001, *p < 0.05. C) Streptavidin immunoblotting of cell lysate after DSA uptake. D) Confocal orthogonal view 
of DSA (red) couptake with TF or CTX (green) in bEnd.3 cells. E,F) Percentage of colocalization of DSA with FITC-TF (E) or FITC-CTX (F). n = 20 ROIs 
from three independent experiments, Mann-Whitney U test, ns = not significant.
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for G3-DSA than for G2-DSA (CTR: 0 ± 0 vs G2-DSA: 
0.7 ± 0.7 vesicles per cell, CTR: 0 ± 0 vs G3 5.2 ± 0.43 vesi-
cles per cell, G3-DSA: 5.2 ± 0.43 vs G2-DSA: 0.7 ± 0.7 
vesicles per cell, n = 28 regions of interest from three cultures, 
one-way ANOVA, P < 0.0001) (Figure 2B). Due to the protein 
core of DSA, fluoro-cytochemistry experiments could be 
matched to a biochemical approach using western blot (WB) 
carried out on cell lysate from DSA-treated cells. Detection of 
the NP core in an independent manner from the fluorescent 
signal excluded false positive data by free fluorescent-dye. NP 
signal was detected in cell lysate as well as in cell pellet con-
firming the uptake of DSA in bEnd.3 cells (Figure 2C). Further-
more, a complete degradation of the protein core within 24 h 
could be excluded. These data indicate that differences in the 
structures and in the amount of positive charges of the den-
drimers trigger the ability of DSA to penetrate brain endothe-
lial cells with a more pronounced uptake for G3-DSA than for 
G2-DSA. In order to exclude a possible positive influence of 
rhodamine label on uptake efficiency, bEnd.3 cells have been 
treated for 24 h with Cy5-labeled DSA. Our results revealed 
highly comparable cell uptake between Rhodamine- and 
Cy5- labeled DSA (data not shown).
The most common uptake mechanism in endothelial cells is 
the caveolae-mediated uptake[32] but it has been demonstrated 
that PAMAM dendrimers are taken up via a clathrin-mediated 
pathway.[33] To better understand the underlying uptake mecha-
nism, we investigated the couptake of DSA with markers for both 
pathways. For that, FITC-transferrin (TF) for clathrin-mediated 
endocytosis and the subunit B of cholera toxin-alexa-fluor-488 
(CTX) for the caveolae-mediated endocytosis were applied in com-
bination with DSA for 24 h to follow the two pathways. Confocal 
microscopy showed colocalization of DSA with both investigated 
endocytosis markers (Figure 2D). Quantitative analysis on z-stacks 
revealed that TF colocalizes for 7.9% ± 2.9% with G2-DSA and for 
7.6% ± 2.12% with G3-DSA (n = 20 regions of interest from three 
cultures, Mann-Whitney U test, P = 0.8881) (Figure 2E). While, 
CTX showed a colocalization of 32.7% ± 4.9% with G2-DSA and 
42.3% ± 4.36% with G3-DSA (n = 20 regions of interest from three 
cultures, Mann-Whitney U test, P = 0.2615) (Figure 2F). These 
data revealed uptake of DSA by both investigated mechanisms 
with no significant difference between G2-DSA and G3-DSA, but 
with a pronounced preference for the caveolae-mediated endo-
cytosis (for G2-DSA = TF: 7.9% ± 2.9% vs CTX: 32.7% ± 4.9% 
n = 20 regions of interest from three cultures, Mann-Whitney U 
test, P < 0.0007; for G3-DSA = TF: 7.6 ± 2.12 % vs CTX: 42.3% ± 
4.36% colocalization with G3-DSA: n = 20 regions of interest from 
three cultures, Mann-Whitney U test, P < 0.0001). In contrast to 
PAMAM dendrimers, the DSA do not follow only the clathrin-
mediated pathway, indicating that the dendrimer hybrids acquire 
different uptake properties compared to dendrimers alone.
2.2. DSA Are Efficiently Transported across the BBB In Vitro
Next, the transport of G2-DSA and G3-DSA from the luminal 
to the abluminal side of porcine and murine BBB transwell 
in vitro models was investigated. In one model porcine brain 
endothelial cells (PBECs) were seeded in the luminal side 
of transwell inserts in a monolayer system (Figure 3A). The 
advantage of primary cells is that they keep features cell lines 
might have lost, like expression of efflux transporters and brain 
capillary specific enzymes important for the physiological func-
tion of the BBB. The porcine model was selected to obtain high 
transendothelial electrical resistance (TEER) values without 
the need of coculturing with astrocytes. Additionally, porcine 
genome, physiology, and anatomy reflect best the human 
biology compared to other laboratory animals.[34,35] To inves-
tigate the ability of DSA to cross the BBB, the percentage of 
transport was defined measuring the rhodamine fluorescence 
in the abluminal compartment after 24 h treatment. In mono-
culture, 15.7% ± 4.2% of G2-DSA (n = 6 wells from three 
cultures in duplicate) compared to 100% G2-DSA (100% ± 4.79, 
n = 6 wells from three cultures in duplicate, one-way ANOVA, 
P < 0.0001) and 19.2% ± 1.56% of G3-DSA (n = 8 wells from four 
Adv. Sci. 2018, 5, 1700897
Figure 3. Transport of DSA in vitro. A,C) Schematic illustration of tran-
swell assay with endothelial cells seeded in monoculture (A) or in triple 
coculture with astrocytes and neurons (C). B,D) Mean relative trans-
port for DSA in porcine monoculture (B) or triple coculture (D). DSA 
(45 µg mL−1) were applied in the luminal compartment and transport was 
quantified relative to transport in insert without cells (100%). one-way 
ANOVA, ***p < 0.001; **p < 0.01, ns = not significant. Porcine monocul-
ture: G2-DSA, 100% G2-DSA n = 6 wells from three cultures in duplicate; 
G3-DSA, 100% G3-DSA n = 8 wells from four cultures in duplicate; triple 
coculture: n = 8 wells from four cultures in duplicate; one-way ANOVA, 
***p < 0.001; **p < 0.01, ns = not significant. (D inset) Streptavidin 
immunoblotting of abluminal medium. E,F) TEER monitoring of NP 
transport assay. TEER values were determined automatically during the 
whole experiment by CellZscope device (E) or at −24 h, 0 h, and +24 h 
from NP application by EVOM system (F). TEER values at t = 0 (DSA 
treatment) were set to 1 and each measurement expressed as relative 
value. Porcine monoculture: CTR n = 6 wells from three cultures in 
duplicate, G2-DSA n = 6 wells from three cultures in duplicate, G3-DSA 
n = 8 from four cultures in duplicate; TEER absolute values in a range 
between 50 and 300 Ω cm2. Triple coculture: n = 8 from four cultures in 
duplicate; TEER absolute values with a mean of 45 ± 13 Ω cm2.
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cultures in duplicate) compared to 100% G3-DSA (100% ± 2.29, 
n = 8 wells from four cultures in duplicate, one-way ANOVA, 
P < 0.0001) were transported to the abluminal compartment 
(Figure 3B). A value of 100% represents the diffusion of DSA 
from luminal to abluminal compartment in inserts without 
cells. Comparing the two generations of dendrimers, no signifi-
cant difference in transport rates could be observed (G2-DSA: 
15.7% ± 4.2% vs G3-DSA: 19.2% ± 1.56%, n = 6–8 wells from 
three to four cultures in duplicate, one-way ANOVA, P > 0.05).
Moreover, transport of DSA was validated in a murine triple 
coculture system using bEnd.3 as endothelial cell lines seeded 
on the luminal side of transwell inserts additionally to primary 
murine astrocytes in the abluminal side and primary murine neu-
rons on the bottom of the abluminal compartment (Figure 3C). 
Since astrocytes and neurons are mainly responsible for the spe-
cialization of brain endothelial cells, the triple-coculture system 
is the best in vitro approach to model the BBB.[36] Using triple-
coculture, 37.8% ± 4.01% of G2-DSA (n = 8 wells from four 
cultures in duplicate) compared to 100% G2-DSA (100% ± 0.93, 
n = 8 wells from four cultures in duplicate, one-way ANOVA, 
P < 0.0001) and 21% ± 1.69% of G3-DSA (n = 8 wells from 
four cultures in duplicate) compared to 100% G3-DSA (100% 
± 2.3, n = 8 wells from four cultures in duplicate, one-way 
ANOVA, P < 0.0001) were transported to the abluminal com-
partment (Figure 3D). Transport was also confirmed by detec-
tion of DSA-streptavidin core in WB carried out on culture 
medium collected from the abluminal compartment after 24 h 
of DSA treatment (Figure 3D, inset). The triple coculture model 
showed a significantly higher transport for G2-DSA compared 
to G3-DSA (G2-DSA: 37.8% ± 4.01% vs G3-DSA: 21% ± 1.69%, 
n = 8 wells from four cultures in duplicate, one-way ANOVA, 
P < 0.05), but it has to be considered that quantification of NP 
in the media did not take into account NP taken up by NVU 
cells in the abluminal compartment also involved in the uptake 
of DSA. Therefore, an underestimation of the real transport 
rate is expected since the total transport of DSA is constituted 
by DSA in abluminal medium + DSA taken up from cells 
seeded at the bottom of the abluminal compartment. In order 
to uncover whether this difference in the transport rate between 
the two discussed models is caused by the preferential cellular 
uptake of G3-DSA, we next determined the estimated DSA frac-
tion incorporated in cells (estimated DSA cellular fraction = 
DSA initial fluorescence – DSA abluminal fluorescence – DSA 
luminal fluorescence) (gray bar; Figure S1, Supporting Infor-
mation). Intriguingly, we observed that for G3-DSA in the triple 
coculture model a considerably higher fraction of fluorescence 
than monoculture vanished from the luminal and abluminal 
compartments (Figure S1A, Supporting Information), while 
for G2-DSA the loss of fluorescence was constant and compa-
rable between the two investigated BBB models (Figure S1B, 
Supporting Information). Indirectly, these results strongly sug-
gest that a higher fraction of G3-DSA than G2-DSA is taken up 
by cells in triple coculture compared to monoculture. In sum-
mary, the data presented in this paragraph show that in both in 
vitro BBB systems, high transport efficiency for G2-DSA and 
G3-DSA from the luminal to the abluminal compartment could 
be observed. The comparison of DSA transport rate (in the 
range from 16% to 38%) and published in vitro transport rates 
highlights strongly the great potential of DSA to efficiently 
target the brain. Performing a comparison between different 
in vitro studies has to be carefully judged, because different 
experimental settings (e.g., the species of cells used, mono- and 
cocultures models) will be compared. In general, high transport 
rates have been demonstrated to be expected mainly in BBB 
models with lower permeability property[37] as well as for nano-
systems employing specific brain-targeting ligands.[38] How-
ever, for DSA the percentage of transport is higher compared to 
published rates of gold-NP (conjugated to therapeutic agent and 
brain-targeted peptide), transferrin receptor-targeted immu-
noliposomes and neutral, anionic, and cationic malto-dextrin 
60 nm nanoparticles showing a percentage of transport which 
varies from 0.4% to 14%.[39] Thus, the high in vitro transport 
efficiency for DSA shows very promising brain-targeting prop-
erties of the investigated PAMAM dendrimer bioconjugates.
Using CellZscope for the porcine monolayer model and EVOM/
Endhom chamber for the triple coculture, we measured the TEER 
before and after the transport to demonstrate that the used BBB 
models showed a tightness of the layer of brain endothelial cells 
high enough to consider transport data as reliable.[40] DSA were 
applied when the absolute TEER values fell in a range between 
50 and 300 Ω cm2 for porcine model or reached a mean value of 
45 ± 13 Ω cm2 for triple coculture. The TEER was not influenced 
by treatment with DSA compared with t = 0 (time point of DSA 
application) (Figure 3E,F). In the triple coculture model the TEER 
even increased slightly during NP treatment for 24 h (Figure 3F). 
Hence, no paracellular leakage due to disruption of the BBB is to 
be expected. Tight junctions restrict paracellular diffusion of hydro-
philic tracers. Compounds such as FITC-dextran 4 KDa (FD4) can 
be used in order to monitor paracellular diffusion. The apparent 
permeability coefficient (Papp) for FD4 was calculated after meas-
urement of FITC-fluorescence in collected abluminal medium. 
The average basal Papp of FD4 was (9.24 ± 3.59) × 10−7 cm s−1 
in our model employing PBECs and (1.28 ± 2.21) × 10−6 in triple 
coculture model. This falls within the range of the basal Papp 
values reported for FD4 in previously published in vitro BBB 
models.[41] These validation experiments confirm the reliability of 
transport data, assuring that the shown efficiency of DSA to cross 
the BBB in vitro is not related to relevant paracellular transport.
2.3. DSA Follow a Transcytotic Pathway without Short-Term 
Intracellular Degradation or Involvement of Autophagic 
Mechanisms
The transport of DSA from the luminal to the abluminal compart-
ment of the transwell models implicates intracellular migration 
and trafficking which starts with the already discussed uptake. 
Multiple intracellular structures and organelles with their own 
identity and functions can be involved in trafficking and trans-
cytocis. To clarify the molecular mechanisms of how DSA cross 
the BBB requires a deep investigation of the many interconnected 
intracellular pathways. The localization of DSA in cellular com-
partments was studied by using specific intracellular markers.
Costaining with early endosome antigen (EEA) and lyso-
somal-associated membrane protein 1 (LAMP-1) were analyzed 
in order to investigate the possible localization of DSA respec-
tively in early endosomes (EE) and late endosomes (LE). Rep-
resentative orthogonal view and animated 3D reconstruction 
Adv. Sci. 2018, 5, 1700897
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from z-stacks revealed colocalization with both intracellular 
compartments in bEnd.3 cells after 24 h of DSA treatment 
(Figure 4A and Videos 1–6). Quantification of colocalization 
of DSA with EE revealed significant generation-dependent dif-
ferences (G2-DSA: 70.7% ± 3.73% vs G3-DSA 33% ± 3.12%, 
n = 24 regions of interest from three cultures, Mann-Whitney 
U test, P < 0.0001) (Figure 4B). By contrast, colocalization of 
DSA with LE showed a lower percentage than for EE and no dif-
ference between G2-DSA and G3-DSA (G2-DSA: 14.3 ± 1.51 % 
vs G3-DSA: 15% ± 1.62%, n = 24 regions of interest from three 
cultures, Mann-Whitney U test, P = 0.7947) (Figure 4C). Short 
trafficking time in EE for G3-DSA might be responsible for 
high uptake and transport rates.
Nonetheless, there were still NP containing vesicles that 
did not colocalize with EE or LE. In order to study in which 
other intracellular compartments DSA localized during traf-
ficking, several other markers of vesicular transport were 
tested. First, using immunocytochemistry, we studied the pos-
sible colocalization of DSA with vesicle-associated membrane 
protein 3 (VAMP3) that has been postulated to be a vesicle 
soluble N-ethylmaleimide-sensitive-factor attachment receptor 
for early and mostly recycling endosomes, although mice with 
a null mutation in the encoding gene preserved intact endocy-
totic pathways.[42] Tridimensional views obtained by confocal 
microscopy did not reveal a colocalization of DSA with VAMP3-
positive intracellular structures (Figure S2A, Supporting Infor-
mation). Furthermore, DSA also did not colocalize with trans-
ferrin-receptor (Figure S2B, Supporting Information). These 
data confirm the hypothesis that the PAMAM-shell acquires 
new features in combination with a streptavidin core and that 
DSA do not preferentially follow a clathrin-mediated pathway, 
in contrast to PAMAM dendrimers as discussed for couptake 
experiments.[33]
Previous findings demonstrated that some biodegradable 
NP can induce autophagy and be sequestered by autophago-
somes.[43] Thus, we further investigated the possible induction 
of autophagy and whether DSA localized in autophagosomes. 
Cultures of bEnd.3 cells were stained with anti-microtubule-
associated protein 1A/1B-light chain 3 (LC3), which is a marker 
for autophagosomes since, during autophagy, a cytosolic form of 
LC3 (LC3-I) is conjugated to phosphatidylethanolamine to form 
an LC3–phosphatidylethanolamine conjugate (LC3-II), which is 
recruited to autophagosomal membranes. Immunocytochem-
istry revealed that only very few NP-containing vesicles might 
colocalize with autophagosomes (G2-DSA: 0.8 ± 0.46 versus 
G3-DSA 1.8% ± 0.86%, n = 17–20 regions of interest from three 
cultures; Mann-Withney U test, P = 0.0244) (Figure S3A,B, 
Supporting Information).
Autophagy can lead to contrary cellular fates because it is 
involved in both beneficial and harmful cellular effects.[44] 
While autophagy is activated at a basal level in most of the cells 
in the body with a role in regulating the turnover of long-lived 
proteins and eliminating damaged structures, high levels of 
autophagy are often an indication of cellular stress. In order to 
address the question of whether DSA treatment might affect 
cellular homeostasis, induction of autophagy in bEnd.3 cells 
was monitored using immunocytochemical and biochemical 
approaches. First, comparing the ratio of LC3-positive-cells/total 
Adv. Sci. 2018, 5, 1700897
Figure 4. Endosomal trafficking of DSA in bEnd.3 cells. A) Confocal orthogonal view for colocalization of DSA-positive vesicles (red) and early 
endosome antigen (EEA; green) for early endosomes, lysosomal-associated membrane protein 1 (LAMP-1; green) for late endosomes in bEnd.3 cells. 
Animated 3D reconstructions can be found in Videos 1–6. Insets: zoom of ROIs with colocalization (yellow). B,C) Quantification of colocalization 
for DSA with early endosomes (B) or late endosomes (C). Data are expressed in percentage of DSA-positive-vesicles partially colocalizing for at least 
40 % with endosomal vesicles. n = 24 ROIs from three cultures; Mann-Whitney U test, ***p < 0.001; ns = not significant.
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number of cells in control culture and NP-treated samples, 
we demonstrated that DSA did not induce authophagy (CTR: 
3.6% ± 0.44%; G2-DSA: 2.8% ± 0.45%; G3-DSA: 2.5% ± 0.35%, 
n = 30 regions of interest from three cultures, one-way ANOVA, 
P = 0.1657) (Figure S3C, Supporting Information). Additionally, 
LC3-II levels can be analyzed to define activation of authopagic 
processes, due to the fact that LC3-II correlates with autophago-
some numbers.[45] To analyze the autophagic flux, we compared 
the measurement of the LC3-II levels as a function of GAPDH 
(loading control) on WB. Bafilomycin A1 (BAF) was used to 
inhibit autophagosome–lysosome fusion to determine the 
activity of autophagic flux.[46] No increase in LC3-II levels was 
observed in bEnd.3 cells treated with DSA for 24 h (CTR + BAF: 
1; G2-DSA + BAF: 0.95 ± 0.14; G3-DSA + BAF: 0.85 ± 0.03, n = 3 
from three cultures, one-way ANOVA, P = 0.4630) (Figure S3D,E, 
Supporting Information). Taken together, these data indicate no 
increase of autophagy in DSA-treated cells with no incidence on 
the ratio of prosurvival/prodeath inputs.
Additionally, since endothelial cells show a relatively high basal 
autophagy,[47] the detection of few NP-containing-autophago-
somes suggests that DSA, in particular G3-DSA given the high 
rate of uptake, might also be incorporated in autophagosomes 
during basal autophagy.
The data presented so far demonstrated the transport of 
DSA by transcytosis. It has to be considered that material 
taken up from outside the cell by endocytosis often is deliv-
ered to lysosomes and there degraded by acid hydrolases. In 
order to study if DSA might be temporarily delivered to lys-
osomes and partly degraded, we detected DSA by WB anal-
ysis in cell lysates after blocking the process of endosomes–
lysosomes fusion with BAF (4 and 24 h treatment). We did 
not observe any change in levels of DSA uptake comparing 
BAF-treated samples with untreated ones (G2-DSA: 1, 
G2-DSA + BAF 4 h: 1.04 ± 0.18, G3-DSA: 1, G3-DSA + BAF 
4 h: 0.97 ± 0.06, G3-DSA + BAF 24 h: 1.02 ± 0.01, n = 3 from 
three cultures, one-way ANOVA, P = 0.9826) (Figure S4A,B, 
Supporting Information). These data suggest the involvement 
of a “proton-sponge” mechanism as already proposed in pre-
vious studies for PAMAM dendrimers,[48] which describes 
that cationic polymers have pH-buffering properties inducing 
endosomal disruption. For this reason, PAMAM dendrimers 
exhibit high transfection efficiency compared to com-
pounds without buffering ability.[49] This fact offers the addi-
tional possibility of using DSA as a promising nanocarrier 
for nucleic acid and siRNA delivery preventing lysosomal 
degradation, one of the limiting steps for successful nucleic 
acid efficiency. In conclusion, the intracellular colocaliza-
tion data presented herein confirm a transcytosis transport, 
which preserves DSA integrity and might involve lysosomal 
escape.
2.4. DSA Do Not Affect bEnd.3 Cells Viability and BBB Integrity
Our nanosystem aims to target the brain without disruption 
or opening of the BBB and without affecting cell viability. Cell 
viability of bEnd.3 cells was challenged for 24 h with DSA 
(400 µg mL−1); applied concentration for uptake and transport 
studies was 45 µg mL−1. Cell vitality assay carried out by alamar 
blue showed no toxicity of the DSA for all concentrations 
(n > 9 wells from four cultures; one-way ANOVA; P > 0.05). On 
the contrary, CTR and serial dilutions of DSA showed high sig-
nificant differences with the staurosporine probe used as toxic 
control (live: 99.8% ± 0.75% vs dead: 1.81% ± 1.37%, n > 9 wells 
from four cultures, one-way ANOVA, P < 0.05) (Figure 5A).
Next, a concentration-dependent impact of DSA on BBB 
integrity was probed. For this purpose, bEnd.3 cells were seeded 
in an ECIS 8-Well chamber and TEER was measured continu-
ously for up to 72 h after DSA application. The DSA concentra-
tion used in the previously discussed experiments (45 µg mL−1) 
showed no significant impact on the barrier integrity (n = 5 
wells from two cultures, two-way ANOVA, P > 0.05) (Figure 5B), 
while high concentrations of DSA (400 µg mL−1) have a low 
reversible impact on barrier integrity (Figure 5C). TEER values 
dropped to 79% for G2-DSA (n = 7 wells from three cultures, 
two-way ANOVA, P < 0.01) and 73% for G3-DSA (n = 7 wells 
from three cultures, two-way ANOVA, P < 0.001) within the first 
40 h. However, barrier integrity recovered to 87% for G2-DSA 
(n = 7 wells from three cultures, two-way ANOVA, P > 0.05) 
and to 89% for G3-DSA (n = 7 wells from three cultures, two-
way ANOVA, P > 0.05) at 72 h during DSA application. In 
agreement with previous studies and established therapies, a 
transient opening of the BBB does not have to be considered 
strictly as a deleterious event but could be considered as a 
system to better deliver molecules to the CNS.[50] Additionally, 
zona occludens 1 (ZO1) staining as marker of tight junctions 
also show maintenance of intact tight monolayer in bEnd.3 
cells treated for 24 h with DSA (45 µg mL−1) (Figure 5D). Thus, 
DSA represent a good biocompatible system which do not dra-
matically affect cell viability or BBB integrity.
2.5. DSA Uptake in Astrocytes and Neurons Occur without 
Cytotoxic Effects
The aim of a successful brain treatment is not only to over-
come the BBB, but also to reach target cells. These target cells 
in CNS diseases might be neurons or astrocytes. To investi-
gate the potential of DSA to target NVU elements, primary 
cells were treated for 24 h, fixed and costained with markers 
for astrocytes (glial fibrillary acidic protein, GFAP) and neu-
rons (ß-III-tubulin). High rate of uptake could be observed 
for both generations of DSA in glial cells (Figure 6A), 
which represent the cell type coming in close contact with 
the tight layer of endothelial cells in BBB. In coculture of 
neurons and astrocytes, ß-III-tubulin stainings revealed 
uptake also in neuronal cells both in cell body and in den-
drites as shown by colocalization of NP-containing vesicles 
(Figure 6B).
As already observed for bEnd.3 cells, G3-DSA showed higher 
uptake properties than G2-DSA in all NVU cells. In addition, 
these data confirmed the previously mentioned hypothesis that 
lower G3-DSA transport values in triple coculture system may 
result from a high uptake in target cells located in the ablu-
minal compartment.
It has to be taken in account that delivery of exogenous mole-
cules might cause side effects. Hence, in order to evaluate whether 
DSA affect cell viability of target cells, alamar blue assay for 
Adv. Sci. 2018, 5, 1700897
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primary murine astrocytes and TUNEL assay for neurons were 
carried out, applying increasing concentrations of DSA from 10 up 
to 400 µg mL−1. After 24 h treatment, alamar blue assay showed 
no changes in astrocyte cell vitality for all the analyzed concen-
trations, even for DSA concentration up to 400 µg mL−1 (n > 9 
from three cultures, one-way ANOVA, P > 0.05) and significant 
differences were observed in comparison with a cytotoxic stauro-
sporine treatment (live: 100.34% ± 1.4% vs dead: 0.5% ± 0.49%, 
n > 9 from three cultures, one-way ANOVA, P < 0.05) (Figure 6C). 
Comparable results were obtained for primary neuronal cultures 
by TUNEL assay. There was no significant increase in apoptotic 
rate for DSA treated neurons (n > 9 from three cultures, one-
way ANOVA, P > 0.05) (Figure 6D), but a significant increase 
could be observed for the control treated with staurosporine (live: 
1 ± 0.03 vs dead: 2.3 ± 0.14, n > 9 from three cultures, one-way 
ANOVA, P < 0.05). These data revealed the ability of DSA to 
penetrate the NVU cells without induced cytotoxic effects.
2.6. DSA Are Transported to the Brain and Taken  
Up by NVU Cells In Vivo
Our in vitro studies showed the potential of DSA to cross the 
BBB, target neuronal cells and therefore potentially act as delivery 
system in clinical applications. The in vitro data presented 
so far demonstrated the importance of the dendrimer shell in 
promoting uptake and transport, which is dependent on the 
dendrimer-generation most likely due to the amount of positive 
charges. Uptake and transport assays proved that G3-DSA are 
more promising for further applications since the higher uptake 
in cells suggests higher efficiency in penetrating endothelial 
cells, crossing the BBB and more easily reaching target cells. For 
this reason, we focused the study on G3-DSA to reach CNS after 
tail intravenous injection in mice. Coronal slices of 30 µm from 
brains isolated by CTR or Cy5-labeled-G3-DSA treated mice 
were carefully analyzed and screened for DSA specific signal.
Three main barrier layers are considered to separate the 
blood and the CNS: the endothelium of the brain microvessels, 
the epithelium of the choroid plexus, and the epithelium of the 
arachnoid mater.[51] Uptake of G3-DSA was easily detectable in 
cells surrounding blood vessels (Figure 7A). G3-DSA were also 
clearly taken up in the meninges in correspondence of the 
second barrier layer represented by the epithelium of the arach-
noid mater (Figure 7B). However, highest uptake was observed 
in the choroid plexus and ventricles, suggesting that G3-DSA 
were released into the cerebrospinal fluid as well (Figure 7C,D). 
These three barriers represent the way through which our DSA 
can access the brain. Therefore, it is not surprising that G3-DSA 
were more easily detectable in areas surrounding the ventricles 
as consequence of the high uptake in that specific brain area 
(Figure 7D). Uptake of G3-DSA into the brain was also con-
firmed by WB analysis on brain lysate. On a PVDF membrane, 
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Figure 5. DSA effect on cell vitality and BBB integrity in vitro. A) bEnd.3 cell vitality by Alamar Blue assay after DSA treatment (24 h). Positive control: 
cell toxin staurosporine. n > 9 wells from four cultures; one-way ANOVA; ***p < 0.001. B,C) Long term impact of DSA on cell integrity investigated 
for 72 h by ECIS. TEER values at t = 0 (DSA treatment) and TEER from CTR measurement were set to 1 and each measurement is expressed as a 
relative value. n (45 µg mL−1) = 5 wells from two cultures; n (400 µg mL−1) = 7 wells from three cultures, two-way ANOVA, ***p < 0.001, **p < 0.01. 
D) Representative epifluorescence microscopy images from bEnd.3 cells culture treated with DSA (red) showing maintenance of BBB integrity by tight 
junctions staining with zona occludens 1 marker (ZO1; green). White arrows indicate representative areas of DSA localization.
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clear bands for DSA were visible after detection of streptavidin 
core (Figure S5, Supporting Information). To more specifically 
identify the localization of DSA within the brain tissue, G3-DSA 
signal was detected in combination with staining for endothelial 
cells using the marker endoglin (CD105), glia using the marker 
GFAP, or neurons using the marker NeuN. CD105 staining 
clearly showed G3-DSA uptake on the lumen side of the ves-
sels as well as in the abluminal brain parenchyma (Figure 7E). 
Lower intensity DSA signals were also detected in target cells: 
astrocytes (Figure 7F) and neurons (Figure 7G). These results 
indicate an effective migration of bioconjugates from blood to 
brain which might follow the hypothesis of permeation from 
endothelial cells to neurons mediated by astrocytes whose end-
feet take up DSA by surrounding the endothelium of blood ves-
sels (Figure 7H).
A comparable mechanism might be responsible for the 
migration of pure PAMAM dendrimers through the corpus 
callosum one-week post intracranial injection described by 
Srinageshwar et al.[52] In order to quantify the amount of 
G3-DSA reaching the brain after intravenous injection, the 
percentage of injected dose (% ID) as well as the concentration 
of G3-DSA expressed in µg/g of brain tissue was calculated. 
The results show that 0.03% ± 0.0% ID (n = 3) and 0.44% ± 
0.03 µg g−1 of brain tissue (n = 3) of G3-DSA efficiently over-
come the BBB and reach the brain in vivo. The obtained trans-
port values are in the range of known dendrimer systems[24,53] 
and show for example a tenfold higher efficiency of trans-
port to the brain in healthy animals compared to a published 
PAMAM G4- hydroxyl-terminated dendrimer.[24] One of the 
crucial points in the study presented here is the BBB penetra-
tion in healthy animals across an intact barrier. Indeed, most of 
already published studies tend to evaluate transport efficiency 
for in vivo disease models in neurological disorders, which 
are often accompanied by BBB impairment. This leads to an 
overestimation of the actual crossing ability of the used nano-
system due to increased BBB permeability in pathological con-
ditions, if transport is not additionally determined in healthy 
animals. In our study, demonstrating high transport efficiency 
across BBB in healthy animals, we can envision even a higher 
transport rate if the BBB is affected by the neurological dis-
orders or in brain cancer, which treatment is addressed to. 
Additionally, the observed G3-DSA brain concentration is in a 
range, which would reach the needed concentration for thera-
peutic molecules like nucleic acids. For example, Tyler et al. 
demonstrated a decrease in gene expression of neurotensin 
receptor using peptide nucleic acids at a brain molecular con-
centration almost fivefold lower than G3-DSA.[54] Nance et al. 
found a % ID of 0.003% (healthy animal) for G4-OH PAMAM 
dendrimer loaded with N-acetylcysteine to efficiently deliver 
the drug load in the diseased animal with 100-fold greater 
brain accumulation compared to free drug.[26] Additionally, 
from observed data it could be supposed that DSA might pro-
tect drug load from lysosomal entrapment holding the possi-
bility of even higher efficiency.
2.7. DSA Are Biodistributed in Many Organs In Vivo, 
Mostly in Kidney and Liver
Although this study aims to investigate DSA transport to the 
brain, additionally the uptake of G3-DSA in other organs was 
investigated. Therefore, after each NP application, kidney, liver, 
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Figure 6. DSA uptake and cytotoxicity in target cells. A,B) Representative confocal 3D orthogonal views of DSA (red) uptake in GFAP-positive astro-
cytes (green) A) and β-tubulin-positive neurons (orange) B). C,D) Cell vitality after DSA treatment (24 h) in astrocytes quantified by Alamar Blue assay 
(C) or in neurons by Fluorometric TUNEL assay (D). Positive control (dead): cell toxin staurosporine. Astrocytes: n > 9 from three cultures; neurons: 
n > 9 wells from three cultures; one-way ANOVA; ***p < 0.001.
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spleen, lung, and heart were also collected and screened for NP 
uptake. G3-DSA showed high uptake rates in kidney and liver 
(Figure S6A,B, Supporting Information). NP signal was also 
detected in the spleen, lung, and heart with lower uptake rates 
(Figure S6C–E, Supporting Information).
Considering the physicochemical properties of DSA, small 
size in the range of 5 nm and positively charged, a high uptake 
in kidney was predictable.[55]
The present data demonstrate high kidney uptake of DSA, 
which could indicate a clearance or renal reabsorption. To fur-
ther investigate the case for DSA, WB analysis on blood samples 
collected 24 h after G3-DSA treatment revealed a circulation of 
the nanocompound indicating that NP were still available for 
uptake (Figure S7, Supporting Information).
2.8. DSA Do Not Affect BBB Integrity In Vivo
To assess the use of DSA for medical applications, the BBB integ-
rity was studied by the use of intravital dyes (tracers, markers) of 
molecular weight greater than 180 Da, which preclude passage 
across an intact barrier. EB (MW 961 Da) is one of the largest 
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Figure 7. G3-DSA transport in vivo. A–D) Representative confocal images of G3-DSA (white) uptake at blood-brain barriers and periventricular area 24 h 
after intravenous injection (450 µg mL−1 blood). E–G) Representative confocal images of G3-DSA (white) uptake in brain endothelial cells (CD105; 
green) (E), astrocytes (GFAP; green) (F), and neurons (NeuN; green) (G) 24 h after intravenous injection (900 µg mL−1). H) Schematic representation 
of possible G3-DSA in vivo trafficking.
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dyes, which in blood binds to the albumin fraction (EBA) to 
give rise to a high-molecular complex (EBA = 68 500 Da).[56] EB 
was intravenously injected 3 h before the end of DSA treatment 
to assess BBB integrity. Analysis of the brains did not show 
macroscopic EB infiltration in brain tissue related to DSA treat-
ment (Figure 8A). Epifluorescence microscopy revealed a local-
ized EB fluorescence in blood vessels without extravasation of 
the dye (Figure 8B). In addition, analysis of brain lysate (meas-
uring the µg of EB g−1 of brain tissue) did not show signifi-
cant change of EB fluorescence compared to the sham animal 
(Sham: 0.17 ± 0.03 µg g−1 of brain tissue versus G3-DSA: 
0.19 ± 0.02 µg g−1 of brain tissue, n = 3 brain lysates from three 
mice, Mann-Whitney U test, P = 0.6905) (Figure 8C). This data 
exclude a correlation between in vivo G3-DSA uptake and BBB 
disruption and proves the biocompatibility of our demdrimer 
protein bioconjugate.
3. Conclusion
Combining in vitro and in vivo approaches by using BBB 
models, NVU cell cultures as well as intravenous injection and 
analysis on tissue of mice, we demonstrated that DSA (I) are 
taken up by neurovascular unit cells, (II) are transported from 
the bloodstream to the brain via transcytosis, (III) are biocom-
patible for NVU cells, and (IV) do not impair BBB integrity.
Showing for the first time a biocompatible and multifunctional 
PAMAM dendrimer bioconjugate which can efficiently target 
the brain via crossing the intact BBB, significantly expands the 
existing potential of dendrimer-based drug delivery systems to 
may be translated into future trials involving CNS pharmaco-
therapies. Additionally, the DSA itself might be applicable as 
antiviral, antitoxin, and antiprion therapeutic agent suitable for 
therapy of CNS infections or it could be tuned for the delivery 
of various therapeutics or diagnostic tracers into the brain. In 
a previous study, Ng et al.[57] successfully demonstrated that 
the tetrameric streptavidin adapter represents a robust scaffold 
for the attachment of biotinylated biological active therapeutic 
molecules.
We envision transporting endogenous molecules or growth 
factors, to complement endogenous mechanism for neuronal 
protection and repair. The observed high uptake into astrocytes 
could have potential for treating reactive gliosis occurring in 
brain traumata, multiple sclerosis and Alzheimer’s disease, by 
loading DSA with nerve growth factor (NGF) as NGF has been 
already shown to be antigliosis and neuroprotective.[58] Nonethe-
less, brain targeted chemotherapeutics may also represent a pos-
sible suitable drug cargo for glioma or brain tumor in general. 
Additionally, DSA could serve as a platform for gene therapy 
approaches. The lysosomal escape mechanism related to the 
cationic nature of DSA points to the possible delivery of nucleic 
acids, which could compensate gene mutations often related 
to neurological disorders. In case of prion diseases, a group of 
fatal neurodegenerative disorders in human and animals,[59]  
PAMAM dendrimers with high surface density of amino 
groups have been shown to be effective in inhibiting prion 
proteins, whose accumulation in CNS is associated to neuro-
logical dysfunction.[16,30] Cationic PAMAM dendrimers are also 
described to inhibit pore formation by binary anthrax toxin 
(PA63) and Clostridium botulinum C2 toxin (C2IIa), thereby 
protecting HeLa and Vero cells from intoxication.[17] Thus, the 
possibility of implementing DSA as therapeutics for treatment 
of prion diseases or bacterial intoxication could be envisioned. 
Furthermore, DSA provide the potential to combine intrinsic 
therapeutic properties of PAMAM dendrimers with therapeutic 
molecules in one system.
4. Experimental Section
Ethical Approval: All experimental procedures were approved by the 
ethical committee of the “Landesuntersuchungsamt Rheinland-Pfalz” 
and the authority “Landesuntersuchungsamt Rheinland-Pfalz” protocol 
number: “Aktenzeichen “23 177-07/G 16-1-024.” Principles of laboratory 
animal care (European, national and international laws) were followed.
Materials: All reagents were obtained from Sigma-Aldrich (Seelze or 
Hamburg, Germany), unless otherwise specified, of analytical grade 
and used as received. Streptavidin from Streptomyces avidinii was 
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Figure 8. G3-DSA effect on BBB integrity in vivo. A) Representative pic-
tures of intact brains showing absence of Evans blue (EB) extravasation 
in sham as well as G3-DSA-treated mice after 24 h from the injection. 
B) Representative epifluorescence microscopy images from brain slices 
showing presence of EB (red) in blood vessels without permeation in 
brain parenchyma in sham and G3-DSA-treated mice. C) EB quanti-
fication in brain lysate from sham and G3-DSA-treated mice. Data are 
expressed as µg of EB per g of brain tissue. n = 3 brain lysates from three 
mice; Mann-Whitney U test; ns = not significant.
www.advancedsciencenews.com
1700897 (12 of 14) © 2018 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
bought from HiSS Dianostics GmbH and was used as is. Vivaspin 6 
ultrafiltration tubes (10 kD MWCO) were purchased from Sartorius. 
Water was purified by a Milli-Q filter system.
The chemical synthesis of generation 2 (G2) and generation 3 (G3) 
PAMAM dendron and subsequent biotinylation was reproduced exactly 
according to the literature.[57,60]
Rhodamine Labeled Streptavidin: Streptavidin (2 mg, 0.038 µmol) was 
dissolved in PBS buffer (2 mL, pH 7.4) and lissamine sulfonyl chloride 
(22 µL, 1 mg mL−1 stock, 0.038 µmol) predissolved in DMSO was 
added and stirred overnight. The reaction solution was purified using 
Vivaspin 6 ultrafiltration tube (10 kD MWCO) with ×3 H2O washes and 
the concentrated salt-free solution was lyophilized to afford rhodamine 
labeled streptavidin in 90% yield.
Cyanine 5 Labeled Streptavidin: Streptavidin (2 mg, 0.038 µmol) 
was dissolved in PBS buffer (2 mL, pH 7.4) and added cyanine-5 NHS 
ester (6.5 µg, 0.0076 µmol) (Biomol GmbH, Hamburg, Germany). The 
reaction solution was shaken overnight on an orbital shaker purified 
using Sephadex G25M (GE Healthcare) size exclusion chromatography. 
The purified fraction was collected and lyophilized to afford the product 
in 92% yield.
Dendronization of Rhodamine/Cy5 Labeled Streptavidin: Rhodamine/Cy5 
labeled streptavidin (1 mg, 0.019 µmol) was dissolved in PBS buffer (1 mL, 
pH 7.4) and added to the respective biotinylated dendron (0.094 µmol). 
The mixture was shaken for 3 h on an orbital shaker and purified using 
Sephadex G25M (GE Healthcare) size exclusion chromatography. The 
fluorescent fractions were collected and analyzed. Analysis of the complex 
was performed on an FPLC (ÄKTA purifier, GE Healthcare), 200 mm 
Superose 6 size exclusion column with tris buffer (50 × 10−3 m, pH 9.0) 
as the eluent (Rv = 14 mL). The corresponding bands containing the 
dendronized protein was identified and lyophilized.
DSA Uptake: DSA were added to cell culture medium (final 
concentration of 45 µg mL−1) for 24 h. For couptake studies DSA were 
applied in combination to transferrin-Alexa Fluor 488 (T13342, Invitrogen, 
120 µg mL−1 ) or cholera toxin B subunit-FITC (C1655, 15 µg mL−1).
Transport Assay: Transport of DSA was investigated in an in vitro 
transwell assay. Cells were seeded in monoculture or triple coculture 
system on BD Fluoroblok TM Inserts (0.3 cm2, pore size 3 µm, 
Corning Incorporated, Corning, USA). DSA (45 µg mL−1) were luminal 
applied. Crossing rate was quantified due to rhodamine labeling of NP. 
Fluorescence was measured with an Infinite F1000 TECAN plate reader 
and the percentage of crossing was calculated. Fluorescence intensity 
in abluminal compartment of transwell system without cells was set 
to 100%. The estimated DSA cellular fraction was obtained as follows: 
estimated cellular fraction = DSA initial fluorescence – DSA abluminal 
fluorescence – DSA luminal fluorescence.
Measurement of Transendothelial Electrical Resistance: TEER in the 
in vitro triple coculture system was determined using an EVOM 
voltohmmeter with an Endohm chamber for 6 mm culture cups (World 
Precision Instruments, Berlin). The final TEER value (Ω × cm2) was 
calculated from measured ohm (Ω) subtracted by the Ω values of 
insert without cells, multiplied by insert surface area of 0.3 cm2. TEER 
and capacitance of the cell layer (Ccl) of a PBECs monolayer on the 
transwell insert was automatically determined by CellZscope system 
(NanoAnalytics, Münster, Germany). When TEER started to increase, 
culture medium was replaced by EBM-2 containing supplements 
(rhFGF-B, rhEGF, GA-100, Ascorbic Acid, R3-ICF-1, Heparin), 
hydrocortisone (550 × 10−9 m), pCPT-cAMP (C3912, 250 × 10−6 m), 
and RO 20–1724 (Calbiochem; 557502, 17.5 × 10−6 m) to induce TEER 
values.[34,61] This BBB model was used for transport and permeability 
experiments.
TEER of a surface attached bEnd.3 monolayer was determined 
using an Electrical Cell Impedance Sensing array (ibidi in cooperation 
with Applied BioPhysics, Martinsried, Germany). Cells were seeded in 
an 8-well chamber (ECIS culture ware 8W10E, ibidi in cooperation with 
Applied BioPhysics, Martinsried, Germany) and were challenged with 
DSA, when cells reached maximal plateau impedance values. For all the 
just described methods, TEER values at time point 0 h were set to 1 and 
data expressed as relative values.
Viability Assay: Cytotoxity on bEnd.3 cells and astrocytes was 
investigated using the cell viability Alamar Blue assay. Cells were DSA-
treated for 24 h after reaching confluence. For viability quantification 
cells were washed with HBSS−/−. Resazurin (R7017, 16.66 µg mL−1) 
in HBSS+++ (100 µL) was added to each well. After 1 h incubation, 
fluorescence was measured spectrophotometrically using a Tecan Infinite 
F1000 plate reader (Tecan, Salzburg, Austria). Fluorescence values were 
corrected to the absorbance of resazurin solution without cells (blank). 
Cell viability (%) was related to untreated control cells (100%).
Cytotoxicity for primary neurons was quantified using a fluorimetric 
TUNEL assay (ROCHE, DNA Fragmentation Imaging Kit, 06432344001, 
Mannheim, Germany), which allows simultaneous quantification of cell 
numbers and apoptotic cells. On DIV 9 cells were challenged with DSA 
for 24 h. To quantify the relative amount of total and apoptotic cells the 
DNA Fragmentation Imaging Kit was used. The relative fluorometric 
TUNEL values were measured with an Infinite F1000 TECAN plate 
reader and relative values for cell numbers and ratio of all groups were 
normalized to untreated control cells. As positive control cells were 
treated with staurosporine (1 × 10−3 m). All experiments were run at least 
three times in triplicates.
NP In Vivo Studies: Cy5-labeled-DSA (450 µg mL−1 blood; or 
900 µg mL−1 blood for NP-positive cells determination and in vivo 
quantification) were administered via the tail vein in P21 mice. CTR 
mice were PBS injected. After 24 h, mice were perfused with PBS 
supplemented with heparin-natrium (Ratiopharm, 5000 E.I.) and 
subsequently with PFA 4%. Brain was collected as well as liver, kidney, 
spleen, lung, and heart. To study in vivo BBB integrity a solution of 2% 
Evans blue (E2129) was administered i.v. for 3 h. To quantify in vivo 
brain uptake, mice were injected with G3-DSA. After 24 h treatment, 
perfusion with PBS/heparin was carried out and brains were weighted, 
homogenized by TissueRuptor (Qiagen) in cell lysate, and incubated 
for 3 h. Subsequently, brain lysates were sonicated (5 cycles of 30 s) 
and centrifuged (4000 × g, 10 min). Cy5-fluorescence for G3-DSA was 
measured by Tecan Infinite F1000 plate reader. % ID and µg/g of brain 
tissue of transported G3-DSA were calculated referring the fluorescence 
values to a calibration curve obtained via serial dilutions of Cy5-DSA in 
brain lysates (modified protocol from Nance et al.).[24]
In Vivo Organ Preparation: Organs were equilibrated in 30% 
sucrose and 30 µm slices were obtained using a freezing microtome 
(Leica CM 1325). Mice to study the BBB integrity after Evans blue 
administration were perfused with PBS/heparin and one hemisphere 
was incubated in TCA (8789, Roth) 50%. Brains in TCA were then 
smashed by TissueRuptor (Qiagen), centrifuged for 25 min at 12000 × g. 
Supernatant was collected and loaded in a 96-well-plate for EB 
fluorescence measurement by Infinite F1000 TECAN plate reader. EB (µg)/ 
brain tissue (g) was calculated referring to a calibration curve in a range 
from 0 to 1 µg mL−1 of EB in TCA.
To generate brain lysate, after treatment and perfusion with PBS/
heparin (Ratiopharm), the collected brain was smashed in lysis buffer 
by TissueRuptor (Qiagen). The homogenate was incubated on a rotation 
wheel 3 h at 4 °C and then centrifuged for 5 min at 2000 × g. Supernatant 
was collected and used for WB analysis. For EB histochemistry detection 
brains were collected fresh without perfusion.
Image Analysis: Images were taken by an IX81 microscope and 
a monochrome fluorescence CCD camera XM10 using the cellˆF 
Software (Olympus) or by a TCS SP5 confocal (Leica). For quantification 
intracellular colocalization, z-stacks were deconvolved by Huygens 
Essential software. For uptake quantification in ImageJ fixed thresholds 
were applied for DAPI and rhodamin signal and fluorescence positive 
particles were counted for each image. DSA positive vesicles per cell are 
blotted. For colocalization studies the percentage of vesicles containing 
DSA colocalizing with the specific intracellular compartment was 
calculated. A threshold of 40% of colocalization for each vesicle was set 
to avoid false positive values. In addition, deconvolved z-stacks were 
also analyzed by JacoP plugin in ImageJ to calculate Van Steensel’s 
crosscorrelation functions as proof of colocalization data.[62]
Data Analysis: All data were analyzed with GraphPad Prism 5 software 
(Graph Pad, La Jolla, CA, USA) and were presented as mean ± SEM. 
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Data were analyzed with the Mann-Whitney U test, ANOVA one-way 
and ANOVA two-way with post hoc test. P < 0.05 was considered as 
statistically significant *, P < 0.01 **, P < 0.001 ***.
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